Dr Reddy's Labs to promote, distribute Sanofi paediatric, adult vaccine brands in India

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-29T14:25:03+05:30 | Updated On 29 March 2024 2:25 PM IST

These brands saw combined sales of approx. Rs 426 crores as per IQVIA MAT February 2024.

Hyderabad: Dr Reddy's Laboratories Ltd., a global pharmaceutical company, has announced that it has entered into an exclusive partnership with Sanofi Healthcare India Private Limited (“SHIPL”) to promote and distribute their vaccine brands across private markets in India.

Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.

These brands saw combined sales of approx. Rs 426 crores (approx. USD 51 million) as per IQVIA MAT February 2024. Sanofi will continue to own, manufacture, and import these brands to the country.

Preeti Futnani, General Manager India for Vaccines, Sanofi, said, “Vaccine confidence has reached its highest in India in the last few years. Yet, there is much to be done for the rest of the country’s large unvaccinated cohort. To fulfil our long-term commitment to India and expand our geographic reach, we’re pleased to partner with Dr. Reddy’s Laboratories (Dr. Reddy’s) for exclusive distribution and promotion. We’re confident this partnership will further bolster our promise of saving millions of lives against vaccines preventable diseases with improved vaccination coverage.”

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said, “We are happy to have the opportunity to leverage our strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi’s well-established and trusted vaccine brands in India. We continue our efforts to become the partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic collaborations. The portfolio now gives Dr. Reddy’s a strong presence in the vaccine segment, propelling us to the second position among vaccines players in India. Through each product and partnership, our aim is to serve over 1.5 billion patients by 2030.”

About the portfolio:

Brand	Label Indication
Hexaxim	Indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilusinfluenzae type b (Hib).
Pentaxim	Indicated for the active immunization of children against Diphtheria, Pertussis, Tetanus, Polio and against invasive infections due to Haemophilusinfluenzae type b bacterium (such as meningitis, septicaemia, etc.) in children from the age of 2 months or according to local recommendations. This vaccine does not protect against infections caused by other types of Haemophilusinfluenzae nor against meningitis due to other micro-organisms.
Tetraxim	Indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis: for primary vaccination in infants from the age of 2 months, for booster vaccination, one year after primary vaccination during the second year of life, for booster vaccination between 5 and 13 years of age, according to official recommendations
Menactra	Indicated for active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y, and W-135. MENACTRA® is approved for use in individuals 9 months through 55 years of age
FluQuadri	FluQuadri is an inactivated quadrivalent influenza vaccine indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine. FluQuadri® is approved for use in persons 6 months of age and older.
Adacel	Indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis (whooping cough) as a single dose in persons aged 11 to 54 years. In accordance with local recommendations, ADACEL® may be considered as an alternative for the fifth dose of tetanus, diphtheria and acellular pertussis vaccine (DTaP) in children 4 to 6 years of age, concomitantly administered with Inactivated Poliomyelitis Vaccine (IPV), at separate sites to complete the vaccination series for this age, when indicated
Avaxim 80U	This vaccine is recommended for the prevention of the infection caused by the Hepatitis A virus in children aged from 12 months to 15 years inclusive

Read also: Sanofi, Cipla collaborate to expand Central Nervous System portfolio reach in India

dr reddys labsdr reddys labs newssanofisanofi healthcare indiahexaximpentaximtetraximmenactrafluquadriadacelavaxim 80U

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751